{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T06:19:06Z","timestamp":1648621146875},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1007\/s11912-004-0068-4","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T16:34:05Z","timestamp":1180715645000},"page":"406-413","source":"Crossref","is-referenced-by-count":6,"title":["Chemoprevention of melanoma"],"prefix":"10.1007","volume":"6","author":[{"given":"Marie-France","family":"Demierre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Merlino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"68_CR1","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1001\/jama.288.14.1719","volume":"288","author":"AC Geller","year":"2002","unstructured":"Geller AC, Miller DR, Annas GD, et al.: Melanoma incidence and mortality among US whites, 1969\u20131999. JAMA 2002, 288:1719\u20131720.","journal-title":"JAMA"},{"key":"68_CR2","first-page":"520","volume":"139","author":"MF Demierre","year":"2003","unstructured":"Demierre MF: Time for the national legislation of indoor tanning to protect minors. Arch Dermatol 2003, 139:520\u2013524.","journal-title":"Arch Dermatol"},{"key":"68_CR3","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/cncr.10593","volume":"94","author":"BK Edwards","year":"2002","unstructured":"Edwards BK, Howe HL, Ries LA, et al.: Annual report to the nation on the status of cancer, 1973\u20131999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002, 94:2766\u20132792.","journal-title":"Cancer"},{"key":"68_CR4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2003.07.173","volume":"21","author":"MF Demierre","year":"2003","unstructured":"Demierre MF, Nathanson L: Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol 2003, 21:158\u2013165. A concise review on chemoprevention as a new strategy in melanoma.","journal-title":"J Clin Oncol"},{"key":"68_CR5","first-page":"1332","volume":"35","author":"MB Sporn","year":"1976","unstructured":"Sporn MB, Dunlop NM, Newton DL, et al.: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976, 35:1332\u20131338.","journal-title":"Fed Proc"},{"key":"68_CR6","first-page":"305","volume":"8","author":"SM Lippman","year":"2002","unstructured":"Lippman SM, Hong WK: Cancer prevention by delay. Clin Cancer Res 2002, 8:305\u2013313.","journal-title":"Clin Cancer Res"},{"key":"68_CR7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/bmj.324.7339.714","volume":"324","author":"P Greenwald","year":"2002","unstructured":"Greenwald P: Science, medicine, and the future: cancer chemoprevention. BMJ 2002, 324:714\u2013718.","journal-title":"BMJ"},{"key":"68_CR8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1145","volume":"3","author":"L Chin","year":"2003","unstructured":"Chin L: The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003, 3:559\u2013570.","journal-title":"Nat Rev Cancer"},{"key":"68_CR9","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1038\/sj.onc.1206450","volume":"22","author":"C Jhappan","year":"2003","unstructured":"Jhappan C, Noonan FP, Merlino G: Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 2003, 22:3099\u20133112.","journal-title":"Oncogene"},{"key":"68_CR10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1471-4914(03)00006-6","volume":"9","author":"G Merlino","year":"2003","unstructured":"Merlino G, Noonan FP: Modeling gene-environment interactions in malignant melanoma. Trends Mol Med 2003, 9:102\u2013108. A comprehensive review on how melanoma genesis represents a potential model of detrimental gene-environment interaction.","journal-title":"Trends Mol Med"},{"key":"68_CR11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/35095108","volume":"413","author":"FP Noonan","year":"2001","unstructured":"Noonan FP, Recio JA, Takayama H, et al.: Neonatal sunburn and melanoma in mice. Nature 2001, 413:271\u2013272.","journal-title":"Nature"},{"key":"68_CR12","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1073\/pnas.0336397100","volume":"100","author":"K Kannan","year":"2003","unstructured":"Kannan K, Sharpless NE, Xu J, et al.: Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci U S A 2003, 100:1221\u20131225.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"68_CR13","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.0022-202x.2001.01601.x","volume":"117","author":"A Demunter","year":"2001","unstructured":"Demunter A, Stas M, Degreef H, et al.: Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol 2001, 117:1483\u20131489.","journal-title":"J Invest Dermatol"},{"key":"68_CR14","first-page":"3468","volume":"8","author":"K Omholt","year":"2002","unstructured":"Omholt K, Karsberg S, Platz A, et al.: Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 2002, 8:3468\u20133474.","journal-title":"Clin Cancer Res"},{"key":"68_CR15","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949\u2013954.","journal-title":"Nature"},{"key":"68_CR16","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1093\/emboj\/19.12.2900","volume":"19","author":"R Busca","year":"2000","unstructured":"Busca R, Abbe P, Mantoux F, et al.: Ras mediates the cAMPdependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J 2000, 19:2900\u20132910.","journal-title":"EMBO J"},{"key":"68_CR17","first-page":"6997","volume":"62","author":"MS Brose","year":"2002","unstructured":"Brose MS, Volpe P, Feldman M, et al.: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002, 62:6997\u20137000.","journal-title":"Cancer Res"},{"key":"68_CR18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","volume":"33","author":"PM Pollock","year":"2003","unstructured":"Pollock PM, Harper UL, Hansen KS, et al.: High frequency of BRAF mutations in nevi. Nat Genet 2003, 33:19\u201320.","journal-title":"Nat Genet"},{"key":"68_CR19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ijc.11722","volume":"109","author":"J Reifenberger","year":"2004","unstructured":"Reifenberger J, Knobbe CB, Sterzinger AA, et al.: Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 2004, 109:377\u2013384.","journal-title":"Int J Cancer"},{"key":"68_CR20","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/jnci\/94.12.894","volume":"94","author":"DT Bishop","year":"2002","unstructured":"Bishop DT, Demenais F, Goldstein AM, et al.: Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002, 94:894\u2013903.","journal-title":"J Natl Cancer Inst"},{"key":"68_CR21","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1086\/323412","volume":"69","author":"NF Box","year":"2001","unstructured":"Box NF, Duffy DL, Chen W, et al.: MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001, 69:765\u2013773.","journal-title":"Am J Hum Genet"},{"key":"68_CR22","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1038\/sj.onc.1206454","volume":"22","author":"MS Soengas","year":"2003","unstructured":"Soengas MS, Lowe SW: Apoptosis and melanoma chemoresistance. Oncogene 2003, 22:3138\u20133151. An excellent review of new insights into the molecular basis for melanoma chemoresistance.","journal-title":"Oncogene"},{"key":"68_CR23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1300","volume":"199","author":"MR Hussein","year":"2003","unstructured":"Hussein MR, Haemel AK, Wood GS: Apoptosis and melanoma: molecular mechanisms. J Pathol 2003, 199:275\u2013288.","journal-title":"J Pathol"},{"key":"68_CR24","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1038\/sj.onc.1206456","volume":"22","author":"VN Ivanov","year":"2003","unstructured":"Ivanov VN, Bhoumik A, Ronai Z: Death receptors and melanoma resistance to apoptosis. Oncogene 2003, 22:3152\u20133161.","journal-title":"Oncogene"},{"key":"68_CR25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1023\/A:1013123532723","volume":"201","author":"D Grossman","year":"2001","unstructured":"Grossman D, Altieri DC: Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001, 201:3\u201311.","journal-title":"Cancer Metastasis Rev"},{"key":"68_CR26","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1073\/pnas.98.2.635","volume":"98","author":"D Grossman","year":"2001","unstructured":"Grossman D, Kim PJ, Schechner JS, et al.: Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A 2001, 98:635\u2013640.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"68_CR27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/excr.2000.4838","volume":"256","author":"SH Kaufmann","year":"2000","unstructured":"Kaufmann SH, Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000, 256:42\u201349.","journal-title":"Exp Cell Res"},{"key":"68_CR28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00008390-199902000-00007","volume":"9","author":"L Serrone","year":"1999","unstructured":"Serrone L, Hersey P: The chemoresistance of human malignant melanoma: an update. Melanoma Res 1999, 9:51\u201358.","journal-title":"Melanoma Res"},{"key":"68_CR29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1471-4914(01)02013-5","volume":"7","author":"K Satyamoorthy","year":"2001","unstructured":"Satyamoorthy K, Bogenrieder T, Herlyn M: No longer a molecular black box: new clues to apoptosis and drug resistance in melanoma. Trends Mol Med 2001, 7:191\u2013194.","journal-title":"Trends Mol Med"},{"key":"68_CR30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/35101078","volume":"1","author":"P Hersey","year":"2001","unstructured":"Hersey P, Zhang XD: How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 2001, 1:142\u2013150.","journal-title":"Nat Rev Cancer"},{"key":"68_CR31","first-page":"7335","volume":"15","author":"P Dhawan","year":"2002","unstructured":"Dhawan P, Singh AB, Ellis DL, et al.: Constitutive activation of Akt\/protein Kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 2002, 15:7335\u20137342.","journal-title":"Cancer Res"},{"key":"68_CR32","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/sj.onc.1206451","volume":"22","author":"H Wu","year":"2003","unstructured":"Wu H, Goel V, Haluska FG: PTEN signaling pathways in melanoma. Oncogene 2003, 22:3113\u20133122.","journal-title":"Oncogene"},{"key":"68_CR33","first-page":"2881","volume":"63","author":"JM Stahl","year":"2003","unstructured":"Stahl JM, Cheung M, Sharma A, et al.: Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003, 63:2881\u20132890.","journal-title":"Cancer Res"},{"key":"68_CR34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1172\/JCI0214891","volume":"109","author":"M Pennati","year":"2002","unstructured":"Pennati M, Colella G, Folini M, et al.: Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest 2002, 109:285\u2013286.","journal-title":"J Clin Invest"},{"key":"68_CR35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/35051606","volume":"409","author":"MS Soengas","year":"2001","unstructured":"Soengas MS, Capodieci P, Polsky D, et al.: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409:207\u2013211.","journal-title":"Nature"},{"key":"68_CR36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ijc.10978","volume":"104","author":"KS Smalley","year":"2003","unstructured":"Smalley KS: A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003, 104:527\u2013532.","journal-title":"Int J Cancer"},{"key":"68_CR37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00008390-200206000-00001","volume":"12","author":"KS Smalley","year":"2002","unstructured":"Smalley KS, Eisen TG: Differentiation of human melanoma cells through p38 MAP kinase is associated with decreased retinoblastoma protein phosphorylation and cell cycle arrest. Melanoma Res 2002, 12:187\u2013192.","journal-title":"Melanoma Res"},{"key":"68_CR38","first-page":"756","volume":"63","author":"K Satyamoorthy","year":"2003","unstructured":"Satyamoorthy K, Li G, Gerrero MR, et al.: Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003, 63:756\u2013759.","journal-title":"Cancer Res"},{"key":"68_CR39","doi-asserted-by":"crossref","first-page":"9790","DOI":"10.1074\/jbc.M212929200","volume":"278","author":"B Govindarajan","year":"2003","unstructured":"Govindarajan B, Bai X, Cohen C, et al.: Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem 2003, 278:9790\u20139795. This study is the first to clearly demonstrate that activation of MAP kinase signaling is an important pathway involved in melanoma transformation.","journal-title":"J Biol Chem"},{"key":"68_CR40","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1046\/j.1523-1747.2002.01854.x","volume":"119","author":"JL Urquhart","year":"2002","unstructured":"Urquhart JL, Meech SJ, Marr DG, et al.: Regulation of Fas-mediated apoptosis by N-ras in melanoma. J Invest Dermatol 2002, 119:556\u2013561.","journal-title":"J Invest Dermatol"},{"key":"68_CR41","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/carcin\/21.3.485","volume":"21","author":"SW Lowe","year":"2000","unstructured":"Lowe SW, Lin AW: Apoptosis in cancer. Carcinogenesis 2000, 21:485\u2013495.","journal-title":"Carcinogenesis"},{"key":"68_CR42","first-page":"3391","volume":"8","author":"RG Fenton","year":"1998","unstructured":"Fenton RG, Hixon JA, Wright PW, et al.: Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras. Cancer Res 1998, 8:3391\u20133400.","journal-title":"Cancer Res"},{"key":"68_CR43","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/22788","volume":"400","author":"L Chin","year":"1999","unstructured":"Chin L, Tam A, Pomerantz J, et al.: Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468\u2013472.","journal-title":"Nature"},{"key":"68_CR44","first-page":"610","volume":"36","author":"T Papp","year":"1999","unstructured":"Papp T, Pemsel H, Zimmermann R, et al.: Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet 1999, 36:610\u2013614.","journal-title":"J Med Genet"},{"key":"68_CR45","first-page":"3955","volume":"63","author":"A Gorden","year":"2003","unstructured":"Gorden A, Osman I, Gai W, et al.: Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003, 63:3955\u20133957.","journal-title":"Cancer Res"},{"key":"68_CR46","first-page":"3883","volume":"63","author":"J Dong","year":"2003","unstructured":"Dong J, Phelps RG, Qiao RF, et al.: BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003, 63:3883\u20133885.","journal-title":"Cancer Res"},{"key":"68_CR47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.0022-202X.2004.22243.x","volume":"122","author":"H Tsao","year":"2004","unstructured":"Tsao H, Goel V, Wu H, et al.: Genetic interaction between NRAS and BRAF mutations and PTEN\/MMAC1 inactivation in melanoma. J Invest Dermatol 2004, 122:337\u2013341.","journal-title":"J Invest Dermatol"},{"key":"68_CR48","first-page":"5761","volume":"63","author":"F Cruz III","year":"2003","unstructured":"Cruz III F, Rubin BP, Wilson D, et al.: Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 2003, 63:5761\u20135766.","journal-title":"Cancer Res"},{"key":"68_CR49","first-page":"2412","volume":"63","author":"D Rimoldi","year":"2003","unstructured":"Rimoldi D, Salvi S, Lienard D, et al.: Lack of BRAF mutations in uveal melanoma. Cancer Res 2003, 63:2412\u20135715.","journal-title":"Cancer Res"},{"key":"68_CR50","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/jnci\/93.14.1062","volume":"93","author":"AA Adjei","year":"2001","unstructured":"Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001, 93:1062\u20131074.","journal-title":"J Natl Cancer Inst"},{"key":"68_CR51","first-page":"710","volume":"22","author":"KT Flaherty","year":"2003","unstructured":"Flaherty KT, Lee RJ, Humphries PJ, et al.: Phase I trial of BAY 43-9006 in combination with carboplatin and paclitaxel. Proc ASCO 2003, 22:710 (abstract 2854).","journal-title":"Proc ASCO"},{"key":"68_CR52","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/35020106","volume":"406","author":"EA Clark","year":"2000","unstructured":"Clark EA, Golub TR, Lander ES, et al.: Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000, 406:532\u2013535.","journal-title":"Nature"},{"key":"68_CR53","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1046\/j.1523-1747.2002.19519.x","volume":"119","author":"EA Collisson","year":"2002","unstructured":"Collisson EA, Carranza DC, Chen IY, et al.: Isoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells. J Invest Dermatol 2002, 119:1172\u20131176.","journal-title":"J Invest Dermatol"},{"key":"68_CR54","first-page":"846","volume":"22","author":"MR Graaf","year":"2003","unstructured":"Graaf MR, Beiderbeck AB, Egberts ACG, et al.: The risk of cancer in users of statins [abstract]. Proc ASCO 2003, 22:846.","journal-title":"Proc ASCO"},{"key":"68_CR55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00045391-200305000-00007","volume":"10","author":"RP Dellavalle","year":"2003","unstructured":"Dellavalle RP, Nicholas MK, Schilling LM: Melanoma chemoprevention: a role for statins or fibrates? Am J Ther 2003, 10:203\u2013210.","journal-title":"Am J Ther"},{"key":"68_CR56","first-page":"10","volume":"9","author":"KK Chan","year":"2003","unstructured":"Chan KK, Oza AM, Siu LL: The statins as anticancer agents. Clin Cancer Res 2003, 9:10\u201319.","journal-title":"Clin Cancer Res"},{"key":"68_CR57","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/jnci\/95.12.844","volume":"95","author":"V Brower","year":"2003","unstructured":"Brower V: Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins. J Natl Cancer Inst 2003, 95:844\u2013846.","journal-title":"J Natl Cancer Inst"},{"key":"68_CR58","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/carcin\/23.3.521","volume":"23","author":"B Agarwal","year":"2002","unstructured":"Agarwal B, Halmos B, Feoktistov A, et al.: Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis 2002, 23:521\u2013528.","journal-title":"Carcinogenesis"},{"key":"68_CR59","first-page":"941","volume":"2","author":"EA Collisson","year":"2003","unstructured":"Collisson EA, Kleer C, Wei M, et al.: Atorvastatin prevents RhoC isoprenylation, invasion and metastasis in human melanoma cells. Mol Cancer Ther 2003, 2:941\u2013948. This is a seminal study demonstrating the potential of statins in melanoma.","journal-title":"Mol Cancer Ther"},{"key":"68_CR60","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1161\/01.RES.83.7.683","volume":"83","author":"M Essig","year":"1998","unstructured":"Essig M, Nguyen G, Prie D, et al.: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. Circ Res 1998, 83:683\u2013690.","journal-title":"Circ Res"},{"key":"68_CR61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF02981932","volume":"73","author":"DL Ornstein","year":"2001","unstructured":"Ornstein DL, Zacharski LR: Treatment of cancer with anticoagulants: rationale in the treatment of melanoma. Int J Hematol 2001, 73:157\u2013161.","journal-title":"Int J Hematol"},{"key":"68_CR62","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615\u20131622.","journal-title":"JAMA"},{"key":"68_CR63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative G","year":"2002","unstructured":"Heart Protection Study Collaborative G: MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7\u201322.","journal-title":"Lancet"},{"key":"68_CR64","first-page":"573","volume":"11","author":"M Lluria-Prevatt","year":"2002","unstructured":"Lluria-Prevatt M, Morreale J, Gregus J, et al.: Effects of perillyl alcohol on melanoma in the TPras mouse model. Cancer Epidemiol Biomarkers Prev 2002, 11:573\u2013579.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"68_CR65","first-page":"1007","volume":"43","author":"BM Powell","year":"2002","unstructured":"Powell BM, Alberts DS, Lluriat-Prevatt M: Preclinical and clinical activity of Apomine, a novel biophosphonate ester, in the prevention and treatment of melanoma [abstract]. Proc Am Assoc Cancer Res 2002, 43:1007.","journal-title":"Proc Am Assoc Cancer Res"},{"key":"68_CR66","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1034\/j.1600-0781.2003.00019.x","volume":"19","author":"S F\u2019Guyer","year":"2003","unstructured":"F\u2019Guyer S, Afaq F, Mukhtar H: Photochemoprevention of skin cancer by botanical agents. Photodermatol Photoimmunol Photomed 2003, 19:56\u201372.","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"68_CR67","doi-asserted-by":"crossref","first-page":"9254","DOI":"10.1038\/sj.onc.1207035","volume":"22","author":"F Afaq","year":"2003","unstructured":"Afaq F, Ahmad N, Mukhtar H: Suppression of UVB-induced phosphorylation of mitogen-activated protein kinases and nuclear factor kappa B by green tea polyphenol in SKH-1 hairless mice. Oncogene 2003, 22:9254\u20139264.","journal-title":"Oncogene"},{"key":"68_CR68","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1245\/ASO.2003.04.033","volume":"10","author":"M Duff","year":"2003","unstructured":"Duff M, Stapleton PP, Mestre JR, et al.: Cyclooxygenase-2 inhibition improves macrophage function in melanoma and increases the antineoplastic activity of interferon gamma. Ann Surg Oncol 2003, 10:305\u2013313.","journal-title":"Ann Surg Oncol"},{"key":"68_CR69","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00008390-200112000-00005","volume":"11","author":"T Vogt","year":"2001","unstructured":"Vogt T, McClelland M, Jung B, et al.: Progression and NSAIDinduced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res 2001, 11:587\u2013599.","journal-title":"Melanoma Res"},{"key":"68_CR70","first-page":"1234","volume":"8","author":"C Zhang","year":"2002","unstructured":"Zhang C, Hazarika P, Ni X, et al.: Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002, 8:1234\u20131240.","journal-title":"Clin Cancer Res"},{"key":"68_CR71","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.1997.03540420035026","volume":"277","author":"MA Tucker","year":"1997","unstructured":"Tucker MA, Halpern A, Holly EA, et al.: Clinically recognized dysplastic nevi: a central risk factor for cutaneous melanoma. JAMA 1997, 277:1439\u20131444.","journal-title":"JAMA"},{"key":"68_CR72","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/cncr.11116","volume":"97","author":"WB Goggins","year":"2003","unstructured":"Goggins WB, Tsao H: A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003, 97:639\u2013643.","journal-title":"Cancer"},{"key":"68_CR73","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/01.MP.0000082394.91761.E5","volume":"16","author":"M Arumi-Uria","year":"2003","unstructured":"Arumi-Uria M, McNutt NS, Finnerty B: Grading of atypia in nevi: correlation with melanoma risk. Mod Pathol 2003, 16:764\u2013771.","journal-title":"Mod Pathol"},{"key":"68_CR74","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/archderm.1994.01690080059007","volume":"130","author":"AA Marghoob","year":"1994","unstructured":"Marghoob AA, Kopf AW, Rigel DS, et al.: Risk of cutaneous malignant melanoma in patients with \u2018classic\u2019 atypical-mole syndrome: a case-control study. Arch Dermatol 1994, 130:993\u2013998.","journal-title":"Arch Dermatol"},{"key":"68_CR75","doi-asserted-by":"crossref","first-page":"458","DOI":"10.7326\/0003-4819-102-4-458","volume":"102","author":"M Greene","year":"1985","unstructured":"Greene M, Clark WH Jr, Tucker MA, et al.: High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985, 102:458\u2013465.","journal-title":"Ann Intern Med"},{"key":"68_CR76","first-page":"119","volume":"2","author":"JA Buckmeier","year":"2003","unstructured":"Buckmeier JA, Einspahr J, Hart NK, et al.: Differential expression of VEGF, CD31, CD105, and p53 in benign nevi, dysplastic nevi and primary melanoma [abstract]. Proc Am Assoc Cancer Res Front Cancer Prev 2003, 2:119.","journal-title":"Proc Am Assoc Cancer Res Front Cancer Prev"},{"key":"68_CR77","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5858\/2001-125-0208-CDEIDN","volume":"125","author":"C Ewanowich","year":"2001","unstructured":"Ewanowich C, Brynes RK, Medeiros L, et al.: Cyclin D1 expression in dysplastic nevi: an immunohistochemical study. Arch Pathol Lab Med 2001, 125:208\u2013210.","journal-title":"Arch Pathol Lab Med"},{"key":"68_CR78","first-page":"314","volume":"8","author":"JA O\u2019Shaughnessy","year":"2002","unstructured":"O\u2019Shaughnessy JA, Kelloff GJ, Gordon GB, et al.: Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002, 8:314\u2013346.","journal-title":"Clin Cancer Res"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-004-0068-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-004-0068-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-004-0068-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T13:19:12Z","timestamp":1628947152000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-004-0068-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["68"],"URL":"https:\/\/doi.org\/10.1007\/s11912-004-0068-4","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}